WallStreetZenWallStreetZen

NYSE: NGVT
Ingevity Corp Stock Forecast, Predictions & Price Target

Analyst price target for NGVT

Based on 5 analysts offering 12 month price targets for Ingevity Corp.
Min Forecast
$40.00+13.12%
Avg Forecast
$50.00+41.4%
Max Forecast
$62.00+75.34%

Should I buy or sell NGVT stock?

Based on 5 analysts offering ratings for Ingevity Corp.
Buy
Strong Buy
1 analysts 20%
Buy
1 analysts 20%
Hold
3 analysts 60%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NGVT stock forecasts and price targets.

NGVT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-05
lockedlocked$00.00+00.00%2024-08-05
lockedlocked$00.00+00.00%2024-08-01
lockedlocked$00.00+00.00%2024-05-07
lockedlocked$00.00+00.00%2024-04-22

1 of 1

Forecast return on equity

Is NGVT forecast to generate an efficient return?
Company
55.51%
Industry
31.78%
Market
54.93%
NGVT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NGVT forecast to generate an efficient return on assets?
Company
6.95%
Industry
10.21%
NGVT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NGVT earnings per share forecast

What is NGVT's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$2.63
Avg 2 year Forecast
$3.80
Avg 3 year Forecast
$4.35

NGVT revenue forecast

What is NGVT's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$1.4B-8.65%
Avg 2 year Forecast
$1.5B-5.68%
Avg 3 year Forecast
$1.5B-0.67%
NGVT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NGVT revenue growth forecast

How is NGVT forecast to perform vs Specialty Chemicals companies and vs the US market?
Company
-2.58%
Industry
2.58%
Market
8.2%
NGVT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NGVT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NGVT vs Specialty Chemical Stocks

TickerPricePrice TargetUp/downsideConsensus
NGVT$35.36$50.00+41.40%Buy
WTTR$10.63$13.75+29.35%Strong Buy
KRO$10.81$11.67+7.93%Sell
MATV$18.01N/AN/A
OEC$16.54$23.00+39.06%Hold

Ingevity Stock Forecast FAQ

Is Ingevity Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: NGVT) stock is to Buy NGVT stock.

Out of 5 analysts, 1 (20%) are recommending NGVT as a Strong Buy, 1 (20%) are recommending NGVT as a Buy, 3 (60%) are recommending NGVT as a Hold, 0 (0%) are recommending NGVT as a Sell, and 0 (0%) are recommending NGVT as a Strong Sell.

If you're new to stock investing, here's how to buy Ingevity stock.

What is NGVT's earnings growth forecast for 2024-2026?

(NYSE: NGVT) Ingevity's forecast annual earnings growth rate of N/A is not forecast to beat the US Specialty Chemicals industry's average forecast earnings growth rate of 20.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.33%.

Ingevity's earnings in 2024 is -$431,300,000.On average, 2 Wall Street analysts forecast NGVT's earnings for 2024 to be $95,587,639, with the lowest NGVT earnings forecast at $79,959,242, and the highest NGVT earnings forecast at $111,216,037. On average, 2 Wall Street analysts forecast NGVT's earnings for 2025 to be $137,929,692, with the lowest NGVT earnings forecast at $125,390,630, and the highest NGVT earnings forecast at $150,468,755.

In 2026, NGVT is forecast to generate $158,101,229 in earnings, with the lowest earnings forecast at $158,101,229 and the highest earnings forecast at $158,101,229.

What is NGVT's revenue growth forecast for 2024-2026?

(NYSE: NGVT) Ingevity's forecast annual revenue growth rate of -2.58% is not forecast to beat the US Specialty Chemicals industry's average forecast revenue growth rate of 2.58%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.2%.

Ingevity's revenue in 2024 is $1,548,400,000.On average, 2 Wall Street analysts forecast NGVT's revenue for 2024 to be $51,408,340,840, with the lowest NGVT revenue forecast at $50,992,189,330, and the highest NGVT revenue forecast at $51,824,492,349. On average, 2 Wall Street analysts forecast NGVT's revenue for 2025 to be $53,080,215,900, with the lowest NGVT revenue forecast at $51,900,817,080, and the highest NGVT revenue forecast at $54,259,614,719.

In 2026, NGVT is forecast to generate $55,898,779,180 in revenue, with the lowest revenue forecast at $55,898,779,180 and the highest revenue forecast at $55,898,779,180.

What is NGVT's forecast return on assets (ROA) for 2024-2026?

(NYSE: NGVT) forecast ROA is 6.95%, which is lower than the forecast US Specialty Chemicals industry average of 10.21%.

What is NGVT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year NGVT price target, the average NGVT price target is $50.00, with the highest NGVT stock price forecast at $62.00 and the lowest NGVT stock price forecast at $40.00.

On average, Wall Street analysts predict that Ingevity's share price could reach $50.00 by Aug 5, 2025. The average Ingevity stock price prediction forecasts a potential upside of 41.4% from the current NGVT share price of $35.36.

What is NGVT's Earnings Per Share (EPS) forecast for 2024-2026?

(NYSE: NGVT) Ingevity's current Earnings Per Share (EPS) is -$11.85. On average, analysts forecast that NGVT's EPS will be $2.63 for 2024, with the lowest EPS forecast at $2.20, and the highest EPS forecast at $3.06. On average, analysts forecast that NGVT's EPS will be $3.80 for 2025, with the lowest EPS forecast at $3.45, and the highest EPS forecast at $4.14. In 2026, NGVT's EPS is forecast to hit $4.35 (min: $4.35, max: $4.35).

What is NGVT's forecast return on equity (ROE) for 2024-2026?

(NYSE: NGVT) forecast ROE is 55.51%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.